EACR-AstraZeneca Circulating Nucleic Acids (cfDNA/ctDNA): In use, in view and on the horizon on January 28-29, 2025 in Nottingham, United Kingdom

This conference offers a holistic understanding of circulating nucleic acids (ctDNA/cfDNA) and ctDNA-/cfDNA-based liquid biopsies. It will cover the current and potential utility of these molecules, how they are built into clinical trial designs to inform patient management, and the multiple measurements required to gain the mostinformation from a blood sample. The discussion will feature examples from breast, lung, colorectal, and bladder cancers. We will review the opportunities and challenges of early cancer detection with minimally invasive approaches and scan the near and far horizon for next generation technologies for liquid biopsy.

The target audience for this conference is:

• senior and junior academic clinicians/trialists
• translational scientists
• lab analysts and technology developers in academic, pharma, and biotech sectors